Why it Matters
On Demand Pharmaceuticals expanded its lobbying team to six firms with Marble Arch LLC‘s July registration. The move comes as the Trump Administration investigates pharmaceutical imports for national security risks. The company has now invested over $290,000 in lobbying since 2020.
By the Numbers
On Demand Pharmaceuticals operates six lobbying firms:
- Omega Strategies LLC: $130,000 (highest engagement)
- Black Diamond Strategies LLC: $50,000
- Marble Arch LLC: New registration
- Strategic Marketing Innovations Inc.: Defense focus
- FisherBroyles LLP: Drug shortages
- Former: MLJ Strategies LLC (ended 2023)
Emma King Doyle leads Marble Arch’s efforts with 55 lobbying disclosures since 2014.
Broader Context
The Trump Administration launched a Section 232 investigation into pharmaceutical imports in April 2025. The probe examines whether drug imports pose national security risks. Commerce could impose tariffs on finished drugs and active pharmaceutical ingredients.
Meanwhile, HHS terminated 3,500 FDA employees in April 2025. The 20% workforce reduction created regulatory uncertainty for pharmaceutical companies. Congress is also considering multiple bills addressing drug shortages and supply chain vulnerabilities.
The Agenda
Marble Arch will focus on pharmacy-related policy issues. The registration doesn’t specify particular legislation or policies. On Demand Pharmaceuticals historically lobbies on three areas: pharmacy issues, budget appropriations, and defense applications. The company promotes mobile pharmaceutical manufacturing for drug shortages and defense needs.
Competitive Landscape
The report doesn’t detail other companies’ lobbying on similar issues. On Demand Pharmaceuticals appears focused on mobile and on-demand drug manufacturing technology. Their lobbying spans defense industrial base policy and pharmaceutical supply chain resilience.
Between The Lines
Congress held hearings on domestic pharmaceutical manufacturing in June 2025. The House Energy and Commerce Committee examined “Made in America” healthcare supply chains. Members acknowledged the drug supply chain is “broken” but remain “far apart” on solutions.
The House also passed legislation restricting pharmaceutical companies receiving federal funding from working with Chinese biotech firms. The FY2025 National Defense Authorization Act includes changes to pharmaceutical procurement rules.
The Bottom Line
On Demand Pharmaceuticals is positioning itself during a critical policy moment. The Section 232 investigation and FDA workforce cuts create both opportunities and risks. The company’s expanded lobbying reflects the high stakes of current pharmaceutical policy debates.
Spot something wrong? Report an issue with this article